Research
Efficacy and Safety of Conventional Disease-Modifying Antirheumatic Drugs in VEXAS Syndrome: Real-World Data from the International AIDA Network
A new study from the AIDA Network VEXAS Registry explores the use of conventional DMARDs in VEXAS syndrome.
Link to article
Among 36 patients, 50% showed partial response, while 18.2% achieved complete remission. Methotrexate demonstrated a glucocorticoid-sparing effect, though no patients discontinued steroids. Combination therapies did not lead to full remission but offered partial benefits. Seventeen adverse events were reported, leading to seven treatment discontinuations. These findings highlight cDMARDs as a viable option in VEXAS management, emphasizing the need for further research.